Please assess the completion status of the following clinical trial:

Trial Title: Risk Factor Control Before Orthopedic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • ≥ 21 years of age~  * Subjects undergoing open orthopedic surgery of the hip, knee or spine~ * Surgery is scheduled at least 3 days after PAT visit and no more than 14 days.~ * High risk subject cohort~    * Coronary artery disease, or~   * Cerebrovascular disease (prior stroke, TIA or carotid artery disease (\>70% stenosis), or~   * Peripheral artery disease, or~   * Prior Venous thromboembolism or arterial thromboembolism, or~   * Age ≥ 60 years and 2 of the following~ * Renal insufficiency (creatinine clearance \< 60ml/min)~ * Diabetes~ * COPD~ * Hypertension~ * Active smoker or stopped less than 30 days prior to consent~ * Cancer (excluding BCC)~ * Heart Failure~Exclusion Criteria:~* • Known intolerance to statins~  * Subject is already on maximum dose statin (atorvastatin/Lipitor 80mg daily or rosuvastatin/crestor 40mg daily)~ * Bilateral renal artery stenosis~ * End stage renal disease (receiving dialysis or CrCl \<30ml/min)~ * Known allergy or intolerance to ACE-inhibitor (other than cough) or Angiotensin receptor blocker (e.g. angioedema, hyperkalemia)~ * Known allergy or intolerance to beta blockers~ * Known sick sinus syndrome not treated with permanent pacemaker~ * Known greater than first degree AV block not treated with a pacemaker~ * Excessive alcohol intake~ * Acute Coronary Syndrome requiring hospitalization within 1 month~ * Stroke within 1 month~ * Known pregnancy~ * Severe co-morbid condition with life expectancy \< 6 months~ * Inability to give informed consent or adhere to follow-up as per protocol~ * Current participation in another investigational drug or device trial

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: ACTIVE_COMPARATOR): Lifestyle counseling (nutrition, physical activity, medication compliance and smoking cessation) Atorvastatin 80mg PO QD Metoprolol 25mg PO BID if HR is elevated Lisinopril 2.5 mg PO QD if SBP is elevated
- Control (Type: NO_INTERVENTION): Standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).